Company insider dossier

Entera Bio Ltd insider intelligence

ENTX filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Biotechnology Data API
50/100

No directional read

35/100 confidence
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Latest evidence
7 Aug 2026

Investment committee read

No directional read

The tape contains filings, but none provide enough priced common-share evidence for a directional classification.

Evidence is contextual

Evidence in favour

  • Participation spans 9 named insiders rather than one filing source.

Decision risks

  • Most filings are awards, derivatives, unpriced common shares, or other securities and remain contextual.
Conviction50No directional read
Confidence35Thin evidence
Named insiders9participating in the tape
Controlled events0directional common-share events
Acquisition value$0normalized amount
Disposal value$0normalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

3.232.682.131.591.04 Acquisition · 7 Aug 2026 · Not reportedAcquisition · 7 Aug 2026 · Not reportedAcquisition · 7 Aug 2026 · Not reportedAcquisition · 7 Aug 2026 · Not reportedAcquisition · 7 Aug 2026 · Not reportedAcquisition · 14 Jul 2026 · Not reportedAcquisition · 14 Jul 2026 · Not reportedAcquisition · 7 May 2026 · Not reportedAcquisition · 7 May 2026 · Not reportedAcquisition · 7 May 2026 · Not reported
Mar 2025Sep 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
2.96 USD
One-week move
+4.2%
Four-week move
-8.4%
Fair-value gap
+67.8%
Trend signal
Active
Relative strength
41.6

Directional balance

Controlled event mix

0%acquisition
Acquisition events
0
Disposal events
0
Net value
$0

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

006 Jul
213 Jul
020 Jul
027 Jul
1503 Aug
010 Aug
017 Aug
024 Aug
031 Aug
007 Sep
014 Sep
021 Sep

Named participants

Insider conviction by person

BURSHTEIN, GREGORYChief of R&D500 events
GALITZER, HILLELChief Operating Officer500 events
YAACOV-GARBELI, DANAChief Financial Officer500 events
ELLIS, SEANDirector500 events
GERMANO, GENO JDirector500 events
MALCA, YONATANDirector500 events
RUBIN, STEVEN DDirector500 events
TAITEL, HAYADirector500 events
TOLEDANO, MIRANDA JAYNEDirector, Chief Executive Officer500 events

Evidence quality

Security and transaction context

Common equity10
Equity compensation0
Options and derivatives10
Other securities0

Role architecture

Who is participating

Director10
CEO and chair4
Other executive4
Finance leadership2

Transaction evidence

Auditable ENTX filing ledger

Showing 1 to 20 of 20.

BURSHTEIN, GREGORYChief of R&D
AcquisitionOptions and derivatives
180000 sharesStock Option (right to buy)
Not reportedContext evidence
ELLIS, SEANDirector
AcquisitionOptions and derivatives
40000 sharesStock Option (right to buy)
Not reportedContext evidence
ELLIS, SEANDirector
AcquisitionCommon equity
20034 sharesOrdinary Shares, par value NIS 0.0000769 per share
Not reportedContext evidence
GALITZER, HILLELChief Operating Officer
AcquisitionOptions and derivatives
200000 sharesStock Option (right to buy)
Not reportedContext evidence
GERMANO, GENO JDirector
AcquisitionOptions and derivatives
43014 sharesStock Option (right to buy)
Not reportedContext evidence
GERMANO, GENO JDirector
AcquisitionOptions and derivatives
50000 sharesStock Option (right to buy)
Not reportedContext evidence
GERMANO, GENO JDirector
AcquisitionCommon equity
25014 sharesOrdinary Shares, par value NIS 0.0000769 per share
Not reportedContext evidence
MALCA, YONATANDirector
AcquisitionCommon equity
22815 sharesOrdinary Shares, par value NIS 0.0000769 per share
Not reportedContext evidence
RUBIN, STEVEN DDirector
AcquisitionOptions and derivatives
43405 sharesStock Option (right to buy)
Not reportedContext evidence
RUBIN, STEVEN DDirector
AcquisitionCommon equity
19117 sharesOrdinary Shares, par value NIS 0.0000769 per share
Not reportedContext evidence
RUBIN, STEVEN DDirector
AcquisitionOptions and derivatives
33368 sharesStock Option (right to buy)
Not reportedContext evidence
TAITEL, HAYADirector
AcquisitionCommon equity
20790 sharesOrdinary Shares, par value NIS 0.0000769 per share
Not reportedContext evidence
TOLEDANO, MIRANDA JAYNEDirector, Chief Executive Officer
AcquisitionOptions and derivatives
200000 sharesStock Option (right to buy)
Not reportedContext evidence
TOLEDANO, MIRANDA JAYNEDirector, Chief Executive Officer
AcquisitionOptions and derivatives
500000 sharesStock Option (right to buy)
Not reportedContext evidence
YAACOV-GARBELI, DANAChief Financial Officer
AcquisitionOptions and derivatives
140000 sharesStock Option (right to buy)
Not reportedContext evidence
TOLEDANO, MIRANDA JAYNEDirector, Chief Executive Officer
AcquisitionCommon equity
347567 sharesOrdinary Shares, par value NIS 0.0000769 per share
Not reportedContext evidence
TOLEDANO, MIRANDA JAYNEDirector, Chief Executive Officer
AcquisitionCommon equity
72993 sharesOrdinary Shares, par value NIS 0.0000769 per share
Not reportedContext evidence
BURSHTEIN, GREGORYChief of R&D
AcquisitionCommon equity
87591 sharesOrdinary Shares, par value NIS 0.0000769 per share
Not reportedContext evidence
GALITZER, HILLELChief Operating Officer
AcquisitionCommon equity
72993 sharesOrdinary Shares, par value NIS 0.0000769 per share
Not reportedContext evidence
YAACOV-GARBELI, DANAChief Financial Officer
AcquisitionCommon equity
58394 sharesOrdinary Shares, par value NIS 0.0000769 per share
Not reportedContext evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context